EFFECT OF KETAMINE NEBULIZATION IN ACUTE RESPIRATORY DISTRESS SYNDROME

THERAPEUTIC EFFECT OF KETAMINE NEBULIZATION IN ACUTE RESPIRATORY DISTRESS SYNDROME: A RANDOMIZED CONTROLLED TRIAL

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/071197

Enrollment

Registered

2024-07-24

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J989- Respiratory disorder, unspecified

Interventions

Intervention1: Ketamine nebulization in Acute Respiratory Distress Syndrome patients.: Group K will be treated with 0.75 mg/kg ketamine (diluted in normal saline to make volume of 5 ml) nebulization 3

Eligibility

Inclusion criteria

Inclusion criteria: Age 20-50 years Mechanically ventilated adult patients admitted to the ICU with developing ARDS.

Exclusion criteria

Exclusion criteria: Pregnant women Patient/Attendant not giving consent Underlying cardiac, and neurological disorders Previous history of psychiatric disorder / substance abuse APACHE Score =25 Patient expiring within 3 days of initiation of therapy.

Design outcomes

Primary

Measure	Time frame
To study the therapeutic effect of ketamine nebulization in ARDS based on Murray Score.Timepoint: 28 Days	—

Secondary

Measure	Time frame
To evaluate effect of ketamine nebulization on 28 days mortality in ARDS patientsTimepoint: 28 days;To evaluate the effect of ketamine nebulization on IL-6 levels in ARDS patients on Day 1, 3 & 5.Timepoint: 5 days	—

Countries

India

Contacts

Public ContactAMNA KHATOON

KING GEORGE MEDICAL UNIVERSITY, LUCKNOW

drraviprakash94@gmail.com9450610553

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026